同方康泰(01312.HK)附屬原料藥證實就對抗武漢肺炎有一定療效
同方康泰(01312.HK)公布,集團接獲工業和信息化部消費品司、重慶市經濟和信息化委員會與重慶市長壽區經濟和信息化委員會的通知,磷酸氯(口奎)(Chloroquine Phosphate)被測試及證實就對抗新型冠狀病毒感染的肺炎有一定的療效。
公司非全資附屬康樂製藥早前已獲國家藥品監督管理局認可為生產原料藥磷酸氯(口奎)(Active Pharmaceutical Ingredients Chloroquine Phosphate)的單位。而因應新型冠狀病毒的爆發,其已恢復生產及製作原料藥磷酸氯(口奎)。同時,集團獲進一步通知康樂製藥被認可生產的原料藥磷酸氯(口奎)現已被納入中央醫藥儲備的名單中。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.